TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · USHealthcareBiotechnology
$10.98-11.67%
Price as of Jul 20, 2026
TNXP growth
Tonix Pharmaceuticals Holding Corp. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +74.8%
- EBITDA
- —
- EBIT
- —
- EPS
- +99.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- +348.3%
- EBITDA
- +110.8%
- EPS
- +76.0%
Three-year CAGR
- Revenue
- +29.9%
- EBITDA
- -64.2%
- EBIT
- +8.0%
- Net income
- +4.6%
- EPS
- +91.7%
- Free cash flow
- -69.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.